Jazz Pharmaceuticals (JAZZ) Income from Continuing Operations (2010 - 2026)

Jazz Pharmaceuticals' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 293100000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 418.59% year-over-year to 293100000.0; the TTM figure through Mar 2026 stood at 29676000.0 (down 93.86% YoY), while the FY2025 annual figure was 355459000.0, down 163.27% from the prior year.
• Income from Continuing Operations was 293100000.0 for Q1 2026 at Jazz Pharmaceuticals, up from 203471000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 293100000.0 in Q1 2026 to a low of 718354000.0 in Q2 2025.
• Historically, Income from Continuing Operations has averaged 41362352.94 across 5 years, with a median of 94638000.0 in 2023.
• The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations sank 641.8% in 2022, then soared 1109.01% in 2023.
• A 5-year view of Income from Continuing Operations shows it stood at 239951000.0 in 2022, then soared by 139.44% to 94638000.0 in 2023, then jumped by 101.96% to 191131000.0 in 2024, then rose by 6.46% to 203471000.0 in 2025, then surged by 44.05% to 293100000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 293100000.0 (Q1 2026), 203471000.0 (Q4 2025), and 251459000.0 (Q3 2025), per Business Quant data.